spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  IBD 

 HSMN NewsFeed - 16 Aug 2024
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jul 2024
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Feb 2024
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2023
Amgen Completes Acquisition of Horizon Therapeutics plc
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Sep 2023
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2022
Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Sep 2022
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI(R)) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 10 Aug 2022
GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 24 May 2022
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Feb 2022
Prometheus Laboratories Announces the Launch of PredictrPK(TM) IFX, A Revolutionary Test Enabling Precision-Guided Dosing for Inflammatory Bowel Disease
Diagnostics Gastroenterology Product Launch
 HSMN NewsFeed - 22 Dec 2021
Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Jul 2021
nanoMesh(TM) LLC (a subsidiary of Exogenesis Corporation) Announces Expansion of the nanoMesh(TM) Product Line Offering to the Clinical Community
Devices Surgery Product Launch
 HSMN NewsFeed - 6 Apr 2021
nanoMesh(TM) LLC (a subsidiary of Exogenesis Corporation) Announces Completion Filing of a Second Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA)
Devices Surgery FDA
 HSMN NewsFeed - 10 Mar 2021
Novum Medical(TM) Appoints Tom Afzal as CEO and Announces Closing of Financing
Devices Orthopaedic Neurosurgery Personnel
 HSMN NewsFeed - 15 Feb 2021
Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 26 Jan 2021
Connect Biopharma Strengthens Leadership Team with Key Hire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Nov 2020
Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 29 Sep 2020
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 17 Jul 2020
Lilly's Mirikizumab Superior to Cosentyx(R) (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 29 Jun 2020
SFA Therapeutics Announces FDA Approval To Begin IND Trial
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 25 Jun 2020
Enterome Completes €46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2020
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 25 Mar 2020
Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Oct 2019
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Sep 2019
Cologuard(R) Gains FDA Approval For Use In Younger Americans, Ages 45 To 49
Diagnostics Oncology FDA
 HSMN NewsFeed - 10 Sep 2019
Cologuard(R) Helps More People Get Screened In A Cost-Effective Way
Diagnostics Oncology
 HSMN NewsFeed - 14 Aug 2019
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 24 Jul 2019
Exogenesis Corporation Announces the Filing of a 510(k) Pre-Marketing Notification Application with the US Food and Drug Administration for Exogenesis Hernia Mesh
Devices Surgery FDA
 HSMN NewsFeed - 17 May 2019
Exact Sciences Presents New Data Reinforcing Performance of Cologuard(R)
Diagnostics Gastroenterology Oncology
 HSMN NewsFeed - 4 Mar 2019
Important New Trial With Oral FERACCRU(R) Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4]
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2019
Cologuard Helps Screen Two Million People for Colorectal Cancer
Diagnostics Oncology
 HSMN NewsFeed - 16 Jan 2019
Therachon is Granted Orphan Drug Designation by US FDA for Apraglutide for the Treatment of Short Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 19 Nov 2018
FDA Approves AEMCOLO(TM) (rifamycin), the First Antibiotic Approved for the Treatment of Travelers' Diarrhea in Over a Decade
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 24 Oct 2018
Inova Diagnostics Launches First FDA Cleared Calprotectin Extraction Device
Devices Diagnostics FDA Product Launch
 HSMN NewsFeed - 22 Aug 2018
Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard(R)
Diagnostics Oncology
 HSMN NewsFeed - 7 Mar 2018
New Blood Test to Accurately Detect Fibromyalgia Now Available from Data Science Company IQuity
Diagnostics Product Launch
 HSMN NewsFeed - 4 Jan 2018
Enterome Raises €32 Million ($38.5 Million) in a Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 Jan 2018
Inova Diagnostics Receives FDA Clearance for the First Fully Automated, Random Access Calprotectin Test
Diagnostics FDA
 HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 26 Sep 2017
Eligo Bioscience Secures $20 Million Series A from Khosla Ventures and Seventure to Bring Precision Medicine to the Microbiome
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Jul 2017
Enterome and Nestlé Health Science Launch New Diagnostics Company
Diagnostics
 HSMN NewsFeed - 8 Jun 2017
Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2017
Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 15 May 2017
BiomX Raises $24 Million in Series A Funding to Develop Microbiome Therapeutics
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Nov 2016
Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 3 Nov 2016
Enterome Appoints Christophe Bonny as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2016
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Apr 2016
Enterome Raises EUR14.5 Million in Series C Financing Round
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 4 Apr 2016
AbbVie Receives CHMP Positive Opinion for HUMIRA(R) (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 2 Mar 2016
Asana Medical, Inc. Names Dr. Christine V. Sapan CEO, Adds University of Miami's Sergio M. Gonzalez to Its Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 17 Feb 2016
Protagonist Therapeutics Names Thomas P. O'Neil Chief Financial Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 10 Sep 2015
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 11 Aug 2015
Celgene Receives Antitrust Clearance for Receptos Acquisition
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Oct 2014
Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announces European site initiation of Phase 3 bile duct cancer trial using photodynamic therapy with PHOTOFRIN(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2014
Shield Therapeutics' ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 6 Nov 2013
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2013
Given Imaging Announces Data Confirming PillCam(R) SB Can Improve Management and Outcomes in Patients With Crohn's Disease
Devices Gastroenterology
 HSMN NewsFeed - 15 Oct 2013
Given Imaging Announces New Studies That Affirm PillCam SB as the Gold Standard for Detecting and Diagnosing Small Bowel Diseases
Devices Gastroenterology
 HSMN NewsFeed - 9 Oct 2013
Integra LifeSciences Announces Introduction of Integra(R) Hollywood(TM) NanoMetalene(TM) Interbody Device
Devices Orthopaedic Neurosurgery Product Launch FDA
 HSMN NewsFeed - 22 Jul 2013
Receptos Announces Appointment of Erle T. Mast as Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 30 Apr 2013
Integra LifeSciences Introduces Hollywood(TM) VI Spinal Fusion System
Devices Orthopaedic Neurosurgery Product Launch
 HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Dec 2012
Avaxia Biologics Raises $6.4 Million in Series B Financing
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 8 Nov 2012
Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2012
Integra LifeSciences Now Offers Zero-Profile, Stand-Alone Interbody Devices for Neck and Lumbar Fixation Procedures
Devices Neurosurgery Orthopaedic
 HSMN NewsFeed - 9 Oct 2012
Integra LifeSciences Receives FDA Clearance for Expanded Indication for Spinal Device
Devices Neurosurgery Orthopaedic FDA
 HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Diagnostics Personalized Medicine Gastroenterology
 HSMN NewsFeed - 11 May 2012
Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Apr 2012
Integra LifeSciences Expands Its Spinal Product Portfolio With a Stand-Alone, Zero-Profile Device for ALIF Procedures
Devices Neurosurgery Orthopaedic
 HSMN NewsFeed - 15 Feb 2012
Santarus Announces FDA Acceptance of UCERIS New Drug Application for Induction of Remission of Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 Feb 2012
Santarus Announces Initiation of Phase IIIb Study with UCERIS in Patients with Mild or Moderate Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 7 Nov 2011
Abbott Presents HUMIRA(R) (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2011
Integra LifeSciences Launches a Zero-Profile, Stand-Alone Interbody Device for Neck Surgery
Devices Orthopaedic Neurosurgery
 HSMN NewsFeed - 31 Oct 2011
Given Imaging Announces New Studies Validate Use of PillCam SB(R) to Detect and Monitor Crohn's Disease
Devices Gastroenterology
 HSMN NewsFeed - 20 Oct 2011
Cook Medical Brings Proven Technology to Canada to Help Prevent Potentially Fatal Catheter-Related Bloodstream Infections with the Spectrum(R) Turbo-Ject(R) PICC
Devices
 HSMN NewsFeed - 3 Oct 2011
Integra LifeSciences Meets Surgeon Demand for User-Friendly Minimally Invasive Spinal Solutions
Devices Neurosurgery Orthopaedic
 HSMN NewsFeed - 11 Apr 2011
Integra LifeSciences Receives FDA Approvals for Three Spinal Fixation Devices
Devices Orthopaedic Neurosurgery FDA
 HSMN NewsFeed - 25 Mar 2011
Crospon and Smart Medical Systems Sign Collaborative Development Deal
Devices
 HSMN NewsFeed - 10 Mar 2011
Given Imaging Receives FDA Clearance for Expanded PillCam(R) SB Indications
Devices Gastroenterology FDA
 HSMN NewsFeed - 18 Aug 2010
Aesculap Implant Systems, Inc. Receives FDA 510(k) Clearance for the A-Fix (SIBD) Spinal System
Devices Orthopaedic Neurosurgery FDA
 HSMN NewsFeed - 13 Aug 2010
Integra LifeSciences Introduces the iPASSAGE(TM) Retractor for Minimally Invasive Spine Surgery
Devices Neurosurgery Orthopaedic
 HSMN NewsFeed - 5 May 2010
New Studies Presented at Digestive Disease Week Highlight the Value of PillCam(R) Capsule Endoscopy
Devices Gastroenterology
 HSMN NewsFeed - 1 Apr 2010
MDRNA, Inc. Acquires Cequent Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Sep 2009
Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Regenerative Medicine
 HSMN NewsFeed - 10 Sep 2009
Pluristem Begins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Regenerative Medicine
 HSMN NewsFeed - 16 Jun 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Regenerative Medicine
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 26 Jan 2009
Sequenom Expands Molecular Diagnostics Portfolio with Acquisition of SensiGen
Diagnostics Acquisitions
 HSMN NewsFeed - 9 Jan 2009
Integra LifeSciences Launches a Series of PEEK-Optima(R) Interbody Spinal Implants
Devices Orthopaedic Neurosurgery
 HSMN NewsFeed - 15 Dec 2008
COSMO ANNOUNCES STRATEGIC COLLABORATION WITH SANTARUS FOR U.S. RIGHTS TO BUDESONIDE MMX® AND RIFAMYCIN SV MMX®
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 11 Dec 2008
New Data Shows Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumour Size
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Oct 2008
New Multicenter Study Underscores Value of Using PillCam(R) SB in Children Younger Than 8
Devices Gastroenterology
 HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Aug 2008
Pluristem Appoints Ms. Chaya Mazouz Clinical Operations Director
Regenerative Medicine Personnel
 HSMN NewsFeed - 9 Jul 2008
Study Shows That PillCam(R) SB Helps Doctors Treat Children With Crohn's Disease More Effectively
Devices Gastroenterology
 HSMN NewsFeed - 30 Jun 2008
William D. Schwieterman, M.D. Joins Chelsea Therapeutics' Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 14 May 2008
Takeda Completes Acquisition of Millennium
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Apr 2008
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 10 Apr 2008
Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Apr 2008
Inotek Focuses Resources on Clinical Programs, Adds to Executive Management Team and Consolidates Operations in Massachusetts
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2008
Titan Spine's ENDOSKELETON(R) TA Passes Test In Competitive Lower Back Pain Market
Devices Neurosurgery Orthopaedic
 HSMN NewsFeed - 4 Mar 2008
UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 8 Feb 2008
Two New Independent Directors Join Chelsea Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2008
Chelsea Therapeutics Begins Patient Dosing in Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2007
Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Dec 2007
Amarin Signs Agreement to Acquire Ester Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 12 Nov 2007
FDA Accepts Chelsea Therapeutics' Investigational New Drug Application for Droxidopa
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Sep 2007
Altheus Therapeutics Secures $3.6 Million in Venture Capital
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Aug 2007
European Commission Grants Chelsea Therapeutics Two Orphan Medicinal Product Designations for Droxidopa
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2007
Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2007
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of LIALDA(TM) (mesalamine) Presented at DDW
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2007
UCB Presents Long-Term CIMZIA(TM) Data in Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 31 Jan 2007
Procter & Gamble Pharmaceuticals Commemorates 15 Years of Trusted Leadership With Asacol(R) (Mesalamine) Delayed-Release Tablets
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 1 Dec 2006
Treatment of Ulcerative Colitis With Asacol Improved Patient Quality of Life in as Early as Three Weeks, According to New Data Analysis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
Given Imaging Announces Data Presented at American College of Gastroenterology Annual Meeting
Devices Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Data Show CIMZIA(TM) (certolizumab pegol) May Improve Productivity in Work and with Daily Activities for People with Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Efficacy Data Show CIMZIA(TM) (Certolizumab Pegol) Maintained Response and Remission in Crohn's Patients Previously Treated With Infliximab
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) in Treatment-Resistant Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 10 Jul 2006
Ocera Therapeutics, Inc. Raises $12 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Jul 2006
Prometheus Launches PROMETHEUS(R) IBD Serology 7
Diagnostics Gastroenterology
 HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2006
Promising Pivotal Phase III Data Show Abbott's Humira(R) (Adalimumab) Maintained Clinical Remission in Patients With Crohn's Disease Through One Year
Biopharmaceuticals Gastroenterology
Return to NewsFeed  

 Additional items found! 44

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 44 additional stories matching:
IBD
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.